| Document |
Document Title |
|
WO/2020/198026A1 |
The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treat...
|
|
WO/2020/198368A1 |
The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disor...
|
|
WO/2020/182723A1 |
The invention relates to herbicidally active 3-phenylisoxazoline-5-carboxamides of s-containing cyclopentenyl carboxylic acid esters of the general formula (I) and to their agrochemically acceptable salts (formula (I)), and to the use th...
|
|
WO/2020/172565A1 |
This document provides methods and materials for increasing or maintaining NMNAT2 polypeptide levels within cells. For example, compounds (e.g., organic compounds) having the ability to increase or maintain NMNAT2 polypeptide levels with...
|
|
WO/2020/168997A1 |
A compound of formula (I) is provided, it can be used in agriculture, particularly used as herbicide for controlling unwanted plants.
|
|
WO/2020/156357A1 |
The present invention relates to a compound having a benzo seven-membered ring structure, a preparation method therefor, and use thereof. The compound has a structure as represented by formula (I). Provided is use of the compound having ...
|
|
WO/2020/157710A1 |
The present invention disclosed 4-substituted isoxazole/isoxazoline (hetero) arylamidine compounds of general formula (I), wherein R1, R2, R3, R4, R4a, R8, R9, A, B and G have the meanings as defined in description. The present invention...
|
|
WO/2020/157069A1 |
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inh...
|
|
WO/2020/156512A1 |
Disclosed in the present invention is an aromatic (hetero)cyclic ether compound having insecticidal activity, or an optical isomer, cis-trans isomer, or agrichemically acceptable salt thereof. Also disclosed in the present invention is a...
|
|
WO/2020/156479A1 |
A cyclopropene- and benzofuran-substituted azaaryl compound, and an intermediate, preparation method and application thereof. Provided are a method for preparing such a compound, a composition containing such a compound, and a use of suc...
|
|
WO/2020/157463A1 |
Disulphide compounds of Formula (I) where Y is sulphuryl or sulphinyl Z is phenyl or substituted phenyl and the other variables are as defined in the claims; pharmaceutical compositions comprising these compounds and methods for making t...
|
|
WO/2020/156106A1 |
Heterocyclic aryl formamides or a salt thereof, a preparation method, a weeding composition, and an application. The structural formula of the heterocyclic aryl formamide compound or the salt thereof is as shown in formula I, and the com...
|
|
WO/2020/149740A1 |
The present invention relates to the field of (auto)immune diseases. The present invention provides heterocyclic compounds having an ROR-yt inhibitory action. It also provides for the use of the compounds as a medicament, in particular f...
|
|
WO/2020/127878A1 |
The present invention relates to a novel method for preparing (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxaz
ol-3-yl]-2-methyl-benzoic acid, which can preferably be used in the synthesis of (5S)-4-[5-(3,5-dichlorophenyl)-5-...
|
|
WO/2020/127944A1 |
The present invention relates to a method for racemizing (5R)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxaz
ol-3-yl]-2-methyl-benzoic acid.
|
|
WO/2020/127935A1 |
The present invention relates to a novel method for preparing (5S)-4-[5-(3,5-di-chlorophenyl)-5-(trifluoromethyl)-4H-isoxa
zol-3-yl]-2-methyl-benzoic acid, which can preferably be used in the synthesis of (5S)-4-[5-(3,5-dichlorophenyl)-5...
|
|
WO/2020/132378A2 |
This invention, in at least some embodiments, relates to an inventive molecule, compositions comprising same, and methods of use thereof for treatment of a neurological disorder.
|
|
WO/2020/127685A1 |
The present invention relates to a compound according to formula I (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositio...
|
|
WO/2020/120141A1 |
A series of functionalised amine derivatives of formula (I) as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammato...
|
|
WO/2020/108538A1 |
An RORĪ³ inhibitor having sulfonyl structure, a preparation method thereof, and a pharmaceutical composition containing a plurality of compounds. The inhibitor has a structure represented by formula (I) or formula (V), wherein the compou...
|
|
WO/2020/106736A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2020/094434A1 |
The invention relates to a process for preparing optically enriched isoxazoline compounds of formula (I), wherein the variables are as defined in the specification, and the shown enantiomer has at least 80% ee; by oxo-Michael addition of...
|
|
WO/2020/088949A1 |
The present invention relates to a process for preparing benzylic amidesof formula (I) wherein the variables are as defined in the specification, and the shown enantiomer has at least 50 % ee; by condensation of a ketone o formula (II) w...
|
|
WO/2020/086728A1 |
In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/064569A1 |
Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, and their uses as insecticides.
|
|
WO/2020/064564A1 |
Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, and their uses as insecticides.
|
|
WO/2020/064565A1 |
The present invention relates to compounds of formula (I) wherein A1, A2, A3, A4, R1, R2, R3, R4 and n are as defined in claim 1; or a tautomer, isomer, enantiomer, salt or N-oxide thereof; to intermediates for preparing compounds of for...
|
|
WO/2020/064560A1 |
The present invention relates to compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds; to intermediate...
|
|
WO/2020/060915A1 |
The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhi...
|
|
WO/2020/058913A1 |
A compound of Formula (I) or or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating hearing loss or balance disorder: Formula (I) wherein R1 and Y are as defined herein.
|
|
WO/2020/060916A1 |
The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhi...
|
|
WO/2020/048476A1 |
Provided are isoxazoline derivatives and uses thereof in agriculture; in particular, provided are a compound having formula (I), a stereoisomer, an N-oxide or a salt thereof, preparation methods thereof, and compositions containing these...
|
|
WO/2020/042114A1 |
Provided herein are methods and compositions for treating liver disorders, including without limitation non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient. Accordingly, utilized herein are compounds of f...
|
|
WO/2020/042841A1 |
A preparation method for (1R,3S)-3-amino-1-cyclopentanol and salts thereof, relating to the field of organic synthesis, wherein the (1R,3S)-3-amino-1-cyclopentanol undergoes an asymmetric cycloaddition reaction with cyclopentadiene by us...
|
|
WO/2020/040343A1 |
The present invention relates to an isoxazole derivative compound of Formula (1) useful as a substance for treating respiratory viral infectious disease caused by coronavirus, in particular, Middle East respiratory syndrome-coronavirus (...
|
|
WO/2020/034945A1 |
The present invention provides a method for preparing a cyclohexane derivative, comprising the following steps: (1) subjecting a compound SM01 and a compound SM02 or a salt thereof to a nucleophilic substitution reaction to obtain a comp...
|
|
WO/2020/034946A1 |
Provided is a method for preparing a cyclohexane derivative, the method comprising the following steps: subjecting a compound, 2-(4-(3,3-dimethylureido)cyclohexyl)acetaldehyde, represented by formula SM01 and a compound represented by fo...
|
|
WO/2020/033382A1 |
Provided are compounds that can act as a modulator of a farnesoid X receptor (FXR) and that can be useful in the treatment of diseases and/or disorders associated with the FXR. Compositions including such compounds are also provided alon...
|
|
WO/2020/022350A1 |
Provided are: an isoxazolin-5-one derivative represented by general formula (1); and a herbicide containing the isoxazolin-5-one derivative as an active ingredient. In the formula, R1 represents a C1-C6 haloalkyl group; Q represents a C3...
|
|
WO/2020/016801A1 |
The present invention relates to compounds of formula (I), to pharmaceutical compositions thereof and to their uses, in particular in the treatment and/or prevention of FXR mediated diseases.
|
|
WO/2019/171234A9 |
The present invention relates to novel heterocyclic compound of Formula (I), (I) wherein, Het, L1, A, L2 and R12 are as defined in the detailed description, for use as fungicides.
|
|
WO/2020/010155A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2020/002587A1 |
A compound of formula (I), or a pharmaceutically acceptable salt thereof.
|
|
WO/2020/006294A1 |
Disclosed herein are methods of treating liver fibrosis by administering calpain inhibitors to subjects in need thereof.
|
|
WO/2019/246109A1 |
Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions.
|
|
WO/2019/243491A1 |
A compound of formula (I), or a pharmaceutical salt thereof.
|
|
WO/2019/229464A1 |
There are described compounds of formula (I): (I) and their use as a medicament in the treatment of diseases associated with the abnormal or elevated catabolism of tryptophan, such as, cancer, immunosuppression, viral infection, depressi...
|
|
WO/2019/215427A1 |
A process for forming a carbon-carbon bond to couple an aryl or heteroaryl group of a first compound with an alkyl or cycloalkyl moietyof a second compound, the process comprising reacting the first compound with the second compound in t...
|
|
WO/2019/217977A1 |
Disclosed herein are compounds represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Values for the variables in Structural Formula I are described herein. The compounds can be used to modulate (e.g, inhib...
|
|
WO/2019/210397A1 |
The present application relates to treatments for bacterial infections. For example, the application relates to the use a gallic acid-sulfamethoxazole conjugate for treatment of a Lactobacillales bacterial infection or a disease, disorde...
|
